Adding Lurbinectedin to First-Line Atezolizumab Maintenance Treatment Prolongs Survival Over Atezolizumab Alone in Patients with ES-SCLC By Ogkologos - July 14, 2025 668 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the IMforte study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Lurbinectedin Zongertinib Shows Durable Antitumour Activity in First-Line Treatment for Patients with Previously Untreated HER2-mutated Advanced NSCLC Patient Guide on Immunotherapy Side Effects and Their Management Now Available Also in the Ukrainian MOST POPULAR 2-Time Cancer Survivor Warns Against Breast Implants After 4 Doctors Missed... June 25, 2019 Dr. Catherine Hamlin, Pioneer In Fistula Surgery, Passes Away At Age... March 23, 2020 Teclistamab Results in a High Rate of Deep and Durable Response... August 22, 2022 Mom Walks In To Comfort Scared Son After Surgery And Sees... June 26, 2019 Load more HOT NEWS New Study Finds Dogs Can Sniff Out Lung Cancer — And... All in the Family – A Story about Genetics and Breast... How Are Eligibility Criteria for Clinical Trials Changing to Help People... EMA Recommends Extension of Therapeutic Indications for Darolutamide
